To improve the website's functionality, we use cookies, including third-party cookies. Read our Privacy Policy for more information

I Agree

Biomarkers Market

Biomarkers Market Analysis By Disease Type (Cardiovascular Diseases, Cancer, Neurological Diseases, Immunological Diseases), By Type (Safety, Efficacy, Validation Biomarkers), By Application (Diagnostics, Drug Discovery & Development, Personalized Medicines & Other Applications) & By Region - Global Market Insights 2022-2032

Analysis of Biomarkers Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Biomarkers Market Outlook (2022-2032)

The global biomarkers market size was valued at US$ 59.1 Billion in 2021 and is expected to expand at a compound annual growth rate CAGR of 15.3% from 2022 to 2032. 

Safety Biomarkers are expected to be the highest revenue generating biomarker type, with a projected growth of 15.9% from 2022–2032.

Biomarkers are characteristics of the body that one can measure. Biomarkers are very critical to medicine in general. People are used to visiting the doctors and getting test results of X-ray results or CT scans.

Biomarkers that tell how the body is doing, and they are measurable. Biomarkers are an integral part of drug research and development processes; they are required, as the tests have to assess the effectiveness of medicines on human beings during clinical investigations.

Report Attributes

Details

Anticipated Base Year Value (2021)

US$ 59.1 Billion

Expected Market Value (2022)

US$ 68 Billion

Projected Forecast Value (2032)

US$ 278 Billion

Global Growth Rate (2022-2032)

15.3%

Market Share of US

55%

Key Companies Profiled

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Epigenetics AG
  • General Electric
  • Johnson & Johnson Services Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Siemens Healthineers AG
  • Qiagen

Don't Need a Global Report?

Save 40% on Country & Region specific reports

Revenue of Biomarkers from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032

As per the Biomarkers industry research by Fact.MR - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value of the Biomarkers industry increased at around 13.6% CAGR, wherein, countries such as the Germany, U.S., China and Japan held significant share in the global market.

The impact of COVID-19 on Biomarkers was not much seen in biomarkers market. Despite the heavy blows to almost all the industries, the Biomarkers industry generated a revenue of US$ 59 Billion in 2021 and continued to grow positively at a rate of 14% over the last year. The reason for the growth of the industry during the pandemic may be credited to the growing health concern of the customers during the pandemic.

The constant surge in urbanization is propelling the demand for various commodities which is consequently driving the need for logistics. Owing to this, Biomarkers market is projected to grow at a CAGR of 15.3% over the coming 10 years.

What Factors are leading to Growth of the Biomarkers industry?

Increasing usage in diagnostics to boost Market Growth

The diagnostic biomarker market has found that breakthroughs in diagnostic tools provide accurate and consistent results in early diagnosis compared to traditional diagnostic tools. Biomarkers are integrated with advanced data management technology and key imaging. Therefore, it meets the needs of early detection and meets the expectations of the market.

Medical practice requires an accurate diagnosis of illness or conditions. Diagnostic biomarkers critically determine whether a patient has a particular medical condition that may require treatment, or whether an individual needs to be enrolled in a clinical trial investigating a particular disease. As is increasingly recognized, many diseases have subtypes that have significantly different prognosis or response to a particular treatment.

Diagnostic biomarkers are used only in symptomatic patients, as opposed to screening biomarkers, which are only applicable to symptomatic individuals. Interestingly, the properties of ideal diagnostic biomarkers are similar to those of screening. In particular, the most established biomarkers for screening can be used as diagnostic markers. Currently available cancer biomarkers are still less diagnostically sensitive and specific with respect to the limitations encountered with diagnostic biomarkers. However, diagnostic biomarkers must be sensitive in order to be good diagnostic biomarkers.

Increase in Cancer Cases Worldwide to Drive Demand for Biomarkers

Wide prevalence of cancer is a key driver of the global biomarkers market. According to a World Health Organization report, cancer is the major reason for deaths around the globe after heart issues. Cancer cases are surging due to the increase in trend of smoking, rise in pollution levels, and poor dietary habits.

Around 235,760 lung cancer cases were reported in the U.S. in 2021. Furthermore, more than 130,000 people lose their lives every year due to lung cancer in the U.S. Lung cancer cases have been rising in other parts of the world as well, with percentage of people smoking reaching around 19% globally.

Around one-third of deaths from cancer are linked to tobacco usage, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries. One of the major factors leading to a rise in their prevalence is lifestyle changes.

Biomarkers Market

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Which Challenges Are Hampering Biomarker Sales?

Availability of other low-cost alternatives to impede Market Growth

Biomarkers need huge investment and capital. This reduces the growth and research of diagnosis and personal medicines. Validation of biomarkers is a time-consuming process. This makes biomarker industries receive low-cost benefits. Also, the availability of cheap alternatives to biomarkers act as a hindrance to the growth of biomarkers market.

Comparative View of Biomarkers Markets

Biomarkers Market :

Attributes

Biomarkers Market

Growth Factor

Increasing prevalence of chronic diseases and constant surge in urbanization is propelling the demand for various commodities which is consequently driving the need for biomarkers.

Opportunity

Increasing use of biomarkers for the treatment of multiple infectious diseases is making a significant impact on the demand for biomarkers, expected to provide opportunities for the growth of the biomarkers market.

Renal Biomarkers Market :

Attributes

Renal Biomarkers Market

Growth Factor

The growing need for identifying kidney diseases to take timely patient management decisions. including the administration of putative therapeutic agents will continue to boost the growth of the renal biomarker market during the forecast period.

Opportunity

Rising prevalence of chronic kidney disease along with high diagnostic screening rates is a key factor driving growth of renal biomarkers market.

Cancer Biomarkers Market :

Attributes

Cancer Biomarkers Market

Growth Factor

Increase in prevalence of various types of cancers, rise in geriatric population across the world, and growth in technological advancements in development of cancer biomarkers are some of the key factors expected to drive the global cancer biomarkers market during the forecast period.

Opportunity

An increase in usage of CEA biomarkers and HER2 biomarkers for detection of cancers such as breast cancer, ovary cancer, thyroid cancer, and small cell lung cancer is also projected to drive the market in the next few years for the growth of the cancer biomarkers market.

Country-wise Analysis

Which Country Topped the Revenue Generation for Biomarkers Market?

Rising Cases of Chronic Disease Fostering Market Growth in the US.

The U.S. dominated the market in 2021 with a market share of over 55%. This is due to increased R & D investment and the local presence of global players. Over the last decade, the number of USFDA-approved drug labels containing molecular biomarker information has increased significantly. In addition, almost all pharmaceutical companies have developed molecular biomarker programs through partnerships or other ventures.

Molecular biomarkers are identified and validated in drug development and used to support drug approval. Approval of such drugs has helped grow the U.S. kidney biomarker market. The American Cancer Society reports that 609,640 people have died of cancer in the country. In 2018, 234,030 cases of lung cancer occurred in the United States, and 154,050 people died of lung cancer.

What is the Growth Projection for Biomarkers Market in Europe?

Presence of Favourable Reimbursement Policies Supporting Market Growth in Europe

Europe held a market share of about 7.1% in the global biomarkers market in 2021 and it is expected to grow at a healthy pace during the next ten years, owing to the rapid expansion of healthcare industry and increase in diagnostic screening for detecting various chronic diseases at earlier stages

Well-established and prominent pharmaceutical companies present in Europe have boosted the growth of biomarkers market in the region. Also, the investment for research and development in is huge. Awareness amongst the masses of early treatment has benefited the biomarkers industry.

Due to the existence of reimbursement policies and programs for both in-patient and outpatient procedures for the diagnosis of diseases, the nation is expected to demonstrate a boost in terms of the total revenue growth of the biomarkers market.

What are the Prospects for Future Biomarkers Sales across Asia Pacific?

Increasing Awareness Among the Consumer to Drive the Market Growth

Biomarkers market is expected to grow at a substantial rate in the forthcoming years. The market in Asia is expected to register the highest CAGR of during the forecast period due to increased demand for Biomarkers in developing countries, especially Japan and China. This increase is also due to the growing awareness among various consumers.

A large share of the region is because of the increasing use of biomarkers in personalized medicine, the various growth strategies of major companies with well-established pharmaceutical companies, and the acceptance of biomarkers primarily for disease diagnosis in cancer diagnosis.

Category-wise Insights

By Type Which Segment Dominates the Biomarkers Market?

Safety Biomarkers Largest Revenue Generator in Biomarkers Market

Safety Biomarkers held the largest share of sales in 2021 with more than 38.0%. It is expected to grow at a CAGR of 15.9% in the next ten years. Recent developments in the Biomarkers market such as Biomarker signatures are enabling various neurological diseases more treatable by the day.

Increasing use of biomarkers for the treatment of multiple infectious diseases is making a significant impact on the demand for biomarkers, which is expected to be continued in the coming years as well. The market for Safety Biomarkers is driven by a high awareness of regular health checks, a low rate of drug consumption, and an increase in the population at high risk of developing various diseases such as cancer, cardiovascular disease and kidney disorders.

Which Disease Type shows the Highest Potential over the Next Ten Years for Biomarkers Market?

Cancer Detection Generate High Revenue in Biomarkers Market

Cancer detection show the highest potential for growth in the biomarkers industry in the disease type segment. It is expected to grow at a rate of about 17.1% during the next ten years.

Around 25 years ago, the clinical utility of Cancer Biomarkers was limited to effective tools for patient prognosis, monitoring, and treatment monitoring. Cancer biomarkers is released from tumor cells or somatic cells in response to the tumor and can be detected in fluids, secretions, or tumor tissues or cells. Cancer biomarkers can be detected in serum, plasma, or whole blood, as well as in whole excrement such as urine, sputum, or CSF.

Therefore, Cancer biomarkers can be evaluated non-invasively and continuously. Evaluating tissue or cell cancer biomarkers requires more invasive techniques than tissue biopsies or serum biomarkers. Cancer biomarkers can be detected in tissues by special techniques, but invasively as a biomarker of serum or urine. Genetic biomarkers can be detected in DNA from tumor tissue, whole blood, or buccal mucosal cells. Therefore, it can be said that biomarkers are expected to continue being the important in the detection of cancer at various stages and helping in its prevention altogether.

Start-Ups for Biomarkers Market

Some key startups in the biomarkers market include Biomarkers Science, Biomarker Strategies, Biomarker pharmaceutical,

  • Biomarker Science is engaged in the identification of disease prevention biomarkers using genomics and proteomics technology, and claim to have discovered numerous biomarkers such as oxidative stress and exercise markers, cartilage degeneration markers and other preventive medicine. They offer services from the planning stage of clinical trials of functional foods and functional materials.

Competitive Landscape

The key players such as F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Epigenetics AG; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc. adopt several organic and inorganic strategies to enhance their revenue and market standings.

Some of the recent developments of key Biomarkers providers are as follows :

  • In May, 2021, Cerascreen KRAS RGQ PCR Kit, the first FDA-approved diagnostic tissue specimen to identify KRAS G12C mutations in QIAGEN NV NSCLC tumors and expand precision medical options for lung cancer, was launched.
  • In April, 2021, F. Hoffmann La Roche Ltd. launched two cardiac biomarker tests, the Sensitive Cardiac Troponin T (cTnThs) and the N-Terminal Pro Brain Sodium Diuretic Peptide Test (NTproBNP). These gold standard biomarkers support the management of cardiovascular disease and may help physicians diagnose heart attacks and better manage heart failure.
  • In July 2020, Thermo Fisher Scientific has signed an agreement with Chugai to expand the use of oncomin Dx targeted tests in patients with non-small cell lung cancer (NSCLC) and accelerate local biomarker tests.
  • In January 2020, in partnership with the Institute for Microbial Technology (CSIRIMTECH), Merck KGaA opened a research institute in Chandigarh, India, with a focus on genome editing, biomarker detection, and life sciences. The facility is equipped with cutting-edge technology needed for on-site students.

Market Segments Covered in Biomarkers Industry Analysis

  • By Disease Type :

    • Cardiovascular Diseases
    • Cancer
    • Neurological Diseases
    • Immunological Diseases
    • Other Disease Types
  • By Type :

    • Safety
    • Efficacy
    • Validation
  • By Application :

    • Diagnostics
    • Drug Discovery & Development
    • Personalized Medicines
    • Other Applications
  • By Region :

    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East & Africa

- Premium Report Details -

Biomarkers Market
  • FACT7181MR
  • Dec-2022
  • Healthcare
  • 170 Pages
  • 72 Tables
  • 148 Figures

- Let's Connect -

Talk To an Expert Today Connect

- Get Started -

Get insights that lead to new growth opportunities

Buy Now

Get A Special pricing for start-ups and universities

Enquiry Before Buying

- Humble, Yet Honored -

Our prestigious clients

- FAQs -

The global Biomarkers market is worth more than US$ 67.6 Billion at present.

Value of Biomarkers are projected to increase at a CAGR of around 15.3% during 2022 – 2032.

Value of Biomarkers increased at a CAGR of around 13.6% during 2017 – 2021.

The main factors driving the growth of the Biomarkers market include an increase in patients suffering from severe diseases, the emergence of technologically advanced treatment procedures and devices, and increasing demand for various sorts of biomarkers.

Top 5 countries driving demand for Biomarkers are U.S., U.K., China, Japan and South Korea.

North America accounted for over 14% of global Biomarkers demand in 2021.

The European market for Biomarkers is projected to expand at a CAGR of around 13% from 2022–2032.

Exclusive Report

Need An Exclusive Report For Your Unique Requirement?

Google translate